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1. Introduction
Defects in epigenetic mechanisms can give rise to several neurological and behavioral
phenotypes. Rett syndrome (MIM 312750) is a pervasive neurodevelopmental disorder that is
primarily caused by mutations in a gene encoding methyl-CpG-binding protein 2. The
functions of the protein are related to DNA methylation, a key epigenetic mechanism that plays
a critical role in gene silencing through chromatin remodeling. Rett syndrome was the first
human disorder in which a link between epigenetic modification and neuronal dysfunction
was discovered. In this chapter, the clinical features and the molecular pathology of Rett
syndrome will be discussed.
1.1. History
Rett syndrome was first recognized by the Viennese pediatrician Andreas Rett. In 1965, he
observed two girls sitting on their mothers’ laps in his waiting room. Both girls were pro‐
foundly intellectually disabled and were continually wringing their hands in the same unusual
manner. Dr. Rett recollected seeing such behavior in previous patients and searched for their
files with his secretary. They found several girls with a similar developmental history and
clinical features. He realized that these symptoms constituted something other than cerebral
palsy, which was the usual designation at the time. In 1966, Dr. Rett published the first
description of the disorder that now bears his name [1]. His paper, however, remained
unnoticed by the medical community until the 1980s, when Swedish child neurologist Bengt
Hagberg with colleagues published the same clinical findings and named the disorder Rett
syndrome [2]. Later, diagnostic criteria were proposed [3], and Rett syndrome became
recognized worldwide by pediatricians, neurologists, geneticists, and neuroscientists. Despite
great effort, the genetic cause of the disorder was not determined until more than 30 years after
the first clinical account. In 1999, mutations within the methyl-CpG-binding protein 2 gene
(MECP2) were identified in patients with Rett syndrome [4], which became a turning point in
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Rett syndrome research. This discovery allowed the molecular confirmation of clinical cases
and contributed to amendments of the diagnostic criteria [5]. Most importantly, this finding
started an extensive investigation into the molecular mechanisms that underlie the pathology
of Rett syndrome.
1.2. Occurence
The estimated prevalence of Rett syndrome is 1:10,000 females by the age of 12 years old [6]
with no specific ethnic or geographical preference. Rett syndrome is one of the leading genetic
causes of profound mental retardation in females, second only to Down syndrome [7]. Male
cases are very rare, and their phenotypic manifestations are different from those observed in
girls with Rett syndrome.
2. Clinical aspects of Rett syndrome
2.1. Symptoms and stages
Rett syndrome, in its classic form, begins to manifest in early childhood and is character‐
ized by neurodevelopmental regression that severely affects motor, cognitive, and commu‐
nications skills.
Prenatal  and  perinatal  periods  are  usually  normal.  Affected  girls  appear  to  develop
normally during the first 6 to 18 months of life and seem to achieve appropriate develop‐
mental  milestones.  Nevertheless,  retrospective analyses of  home videos often show that,
even during this  period,  affected female  infants  display  some suboptimal  development.
This underdevelopment may include subtle motor and behavioral abnormalities, as well as
hypotonia  and  feeding  problems.  General  mobility  and  eye-hand  coordination  may  be
inadequate, and an excess of repetitive hand patting can be observed even during the first
year of life. However, the overall developmental pattern is not obviously disturbed. The
child is usually quiet and placid, and the parents often describe the child as “very good”
[1, 8-11]. The characteristic clinical features appear successively over several stages, forming
a distinctive disease progression pattern (Figure 1).
Stage  I:  Early  onset  stagnation  (age  of  onset:  6-18  months).  Psychomotor  development
begins to slow, but the general developmental pattern is not significantly abnormal. The
deceleration  of  head  growth  (which  eventually  leads  to  microcephaly),  growth  retarda‐
tion, and weight loss occur in most patients. The child is delayed or ceases in the acquisi‐
tion  of  skills.  Although  babbling  and  new  words  may  appear,  language  skills  usually
remain poor. A girl with Rett syndrome may become irritable and restless, and she may
begin to display some autistic features, such as emotional withdrawal and indifference to
the surrounding environment [11, 13, 14]
Stage II: Developmental regression (age of onset: 1-4 years). This stage may occur over a
period of days to weeks and is characterized by a rapid reduction or loss of acquired skills,
especially purposeful hand use, speech, and interpersonal contact [15]. In some patients, the
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decline of motor and communicative performances is more gradual. Interest in people and
objects is diminished, but eye contact may be preserved [11]. Voluntary hand use, such as
grasping and reaching out for toys, is replaced with repetitive stereotypic hand movements,
the hallmark of Rett syndrome. Patterns consisting of wringing, hand washing, mouthing,
clapping, rubbing, squeezing, and other hand automatisms occur during waking hours [1, 16,
17]. Febrile seizures are often present, and epileptic paroxysms occur in most patients [18, 19].
The severity of seizures can vary, ranging from relatively mild or easily controlled by medi‐
cation to severe drug-resistant episodes [20]. Irregular breathing patterns, such as episodes of
hyperventilation, breath holding, and aerophagia, usually develop toward the end of the
regression period. Panting, spitting, and hypersalivation are also frequent symptoms [8, 21].
Stage III: Pseudostationary period (age of onset: 4-7 years, after stage II). This stage can last
for years or decades and is characterized by a relative stabilization of the disorder course.
Patients may recover some skills, which were lost during the regression stage. Patients can
become more joyful and sociable, and they may use eye pointing as a typical way to commu‐
nicate and to express their needs. Some patients may even learn new words and use simple
phrases in a meaningful way. Nevertheless, they continue to suffer from gross cognitive
impairments [14]. Despite improved eye contact and non-verbal communication ability, the
loss of motor functions further progresses in this stage. Stereotypic hand movements become
prominent, as do breathing irregularities. Many patients develop scoliosis, which is often
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Figure 1. Onset and progression of Rett syndrome [12]
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rapidly progressive and eventually requires surgical treatment. Cold feet and lower limbs,
with or without color and atrophic changes, are also common. These conditions occur due to
poor perfusion, which is a consequence of altered autonomic control. Sleeping patterns are
often disturbed and are characterized by frequent nighttime waking and daytime sleeping.
Unexplained night laughing, sudden agitation and crying spells may also be present [11].
Stage IV: Late motor deterioration (age of onset: 5-15 years, after stage III). Non-verbal
communication and social skills continue to improve gradually. Despite persistent serious
cognitive impairment, older patients with Rett syndrome are usually, in contrast to patients
with childhood autism, sociable and pleasant with others [22]. Seizures become less frequent
and less severe, and stereotypic hand movements become less intense. However, motor
deterioration continues with age. Most patients, who previously could walk, become nonam‐
bulatory and wheelchair-dependent. Decreased mobility leads to pronounced muscle wasting
and rigidity, and, at older ages, the patients often develop Parkinsonian features [11, 23, 24].
Females  with  Rett  syndrome often  survive  into  adulthood and older  age,  but  their  life
expectancy is  less  than that  of  the healthy population.  The estimated annual  death rate
from Rett syndrome is 1.2%. Approximately 25% of these deaths are sudden and they may
occur due to autonomic nervous system disturbances or cardiac abnormalities [25-27].
Many  other  features  are  associated  with  Rett  syndrome,  but  they  are  not  considered
diagnostic. The patients are generally small for their age [28], which may be due to poor
self-feeding abilities and problems with chewing and swallowing. They often suffer from
gastroesophageal reflux and bloating. Decreased intestinal motility often results in severe
constipation.  Electroencephalogram  results  tend  to  be  abnormal  but  without  any  clear
diagnostic pattern. A prolonged QTc interval is observed in many patients and presents a
risk for cardiac arrhythmia [26].
2.2. Rett syndrome variants
At least five atypical variants have been delineated in addition to classic Rett syndrome. These
variants do not have all of the diagnostic features, and they are either milder or more severe
than the classic form.
The most common atypical variant of Rett syndrome is “forme fruste”. This mild variant is
characterized by a protracted clinical course with partially preserved communication skills
and gross motor functions. Other neurological abnormalities that are typical for Rett syndrome
are more subtle and can be easily overlooked in this variant [30]. The mild forms of Rett
syndrome also include the late regression variant, which manifests in patients of preschool or
early school age [30], and the preserved speech variant (also called the Zappella variant) in
which patients have preserved language skills and normal head sizes [31].
Severe variants include the early-onset seizure variant (the Hanefeld variant) with the onset
of seizures before the age of 6 months [32] and the congenital variant, which is rare and lacks
the early period of normal psychomotor development [33]. The Hanefeld variant is often
caused by mutations in the CDKL5 gene [34], and most cases of the congenital variant are
related to mutations in the FOXG1 gene [35]. These genetic abnormalities raise the question of
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whether these variants are separate clinical entities, different from MECP2-related Rett
syndrome [11].
2.3. Diagnostic criteria
Despite a known genetic cause, Rett syndrome remains a clinical diagnosis. Its diagnosis is
based on several well-defined criteria (Table 1), which were revised several times over the past
few decades, most recently in 2010 [29].
Consider Rett syndrome diagnosis when postnatal deceleration of head growth is observed
Required for classic Rett syndrome
1. A period of regression followed by recovery or stabilization
2. All main and all exclusive criteria
3. Supportive criteria are not required, although often present in classic Rett syndrome
Required for atypical or variant Rett syndrome
1. A period of regression followed by recovery or stabilization
2. At least 2 of 4 main criteria
3. 5 out 11 supportive criteria
Main criteria
1. Partial or complete loss of acquired purposeful hand skills
2. Partial of complete loss of acquired spoken language
3. Gait abnormalities: impaired ability (dyspraxia) or absence of ability (apraxia)
4. Stereotypic hand movements such as hand wringing/squeezing, clapping/tapping, mouthing and washing/
rubbing automatisms
Exclusion criteria for classic Rett syndrome
1. Brain injury secondary to trauma (perinatally or postnatally), neurometabolic disease or severe infection that cause
neurological problems
2. Grossly abnormal psychomotor development in the first 6 months of life
Supportive criteria for atypical or variant Rett syndrome
1. Breathing disturbances when awake (hyperventilation, breath-holding, forced expulsion of air or saliva, air
swallowing)
2. Bruxism when awake (grinding or clenching of the teeth)
3. Impaired sleep pattern
4. Abnormal muscle tone
5. Peripheral vasomotor disturbances
6. Scoliosis/kyphosis
7. Growth retardation
8. Small cold hands and feet
9. Inappropriate laughing/screaming spells
10. Diminished sensitivity to pain
11. Intense eye communication and eye-pointing behavior
Table 1. Diagnostic criteria for Rett syndrome [29]
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3. The genetics of Rett syndrome
3.1. Mapping of the causative gene
The mode of inheritance of Rett syndrome was difficult to identify because more than 99%
of  the  cases  are  sporadic,  and  the  patients  rarely  reproduce.  Therefore,  the  traditional
genome-wide linkage analysis was not an applicable method for mapping the disease locus.
The  lack  of  males  manifesting  the  classic  Rett  syndrome  phenotype  together  with  the
occurrence  of  families  with  affected half-sisters  suggested an  X-linked dominant  inheri‐
tance  with  lethality  in  hemizygous  males  [2,  36].  Focused  exclusion  mapping  of  the  X
chromosome in available familial  cases was used to narrow down the candidate region,
and the subsequent  analysis  of  candidate  genes in  the patients  finally  revealed disease-
causing mutations in the MECP2 gene [4].
3.2. MECP2 gene
The MECP2 gene (MIM 300005) is located on Xq28 and undergoes X chromosome inactivation
(XCI) in females [37, 38]. The gene spans approximately 76 kb and consists of four exons, which
encode methyl-CpG-binding protein 2 (MeCP2). Alternative splicing of exon 2 and several
polyadenylation signals in a conserved and unusually long 3’ untranslated region (3’UTR) give
rise to eight different transcripts regulated in a tissue-specific and developmental stage-specific
manner [39-42]. For example, the shortest transcript (1.8 kb) is predominant in adult muscles,
heart, blood, and liver. The longest transcript (10.2 kb) occurs at the highest levels in the brain
[41, 42]. The unique expression patterns of each transcript suggest a specific biological
significance, such as a role in mRNA stability, nuclear export, folding, and sub-cellular
localization, thus affecting the levels of the resulting protein [39]. The longest transcript also
has one of the longest 3’ UTR tails in the human genome (8.5 kb), with several blocks of highly
conserved residues between the human and mouse genomes. These findings argue in favor of
a potential regulatory role of the 3’ UTR of the MECP2 gene [43].
3.3. MECP2 mutations
Mutations in the MECP2 gene are identified in 90-95% of classic Rett syndrome patients [4,
44]. Because only the coding region and the adjacent non-coding parts of the gene are routinely
analyzed, it is highly probable that mutations in more remote regulatory elements are
responsible for the rest of the cases. The frequency of MECP2 mutations in patients with
atypical Rett syndrome variants varies considerably between studies. However, the frequency
is generally lower (only 20-70% of patients have MECP2 mutations) than in the classic form
[44-46], suggesting that mutations of regulatory elements or other genes are involved more
often in atypical Rett syndrome than in the classic Rett syndrome. The identification of CDKL5
mutations in the Hanefeld variant and FOXG1 mutations in the congenital variant strongly
support the latter idea.
According to the Human Gene Mutation Database [47], more than 550 mutations have been
identified in the MECP2 gene in patients with Rett syndrome. The spectrum of mutations is
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heterogeneous, including missense and nonsense mutations, deletions, insertions, duplica‐
tions, splice-site mutations, and large deletions of several exons or the entire MECP2 gene.
More than 99% of the mutations occur de novo and mostly originate on the paternal X chro‐
mosome, which explains the high occurrence of Rett syndrome in the female gender [4, 48,
49]. Familial cases of Rett syndrome (mostly affected sisters or maternal half-sisters) are very
rare. MECP2 mutations in these patients are inherited from an asymptomatic or very mildly
affected mother, who carries a somatic mutation, but does not manifest the full pathogenic
phenotype due to favorable XCI pattern [50, 51]. Another explanation for transmission of a
MECP2 mutation to the next generation is a germline mosaicism for a mutation. It is suggested
when the MECP2 mutation identified in several affected children is not present in somatic cells
of their parents [51, 52].
The majority of point mutations in the MECP2 gene are C>T transitions, presumably resulting
from the spontaneous deamination of methylated cytosines [53]. The mutations are scattered
throughout the coding sequence and splice sites, with the exception of exon 2. The eight most
common mutations, which are also C>T transitions, account for approximately 70% of the Rett
syndrome cases. Approximately 10% of cases are due to deletions, which are mostly clustered
in the terminal segment of the coding region [12].
3.4. MECP2 mutations in males and other disorders
Mutations in the MECP2 gene have long been considered lethal in hemizygous males, and Rett
syndrome has been assumed to be exclusively a female disorder. More recently, MECP2
mutations were not only identified in males but also in females with phenotypes different from
Rett syndrome. MECP2-related disorders thus represent a broad spectrum of phenotypes in
both genders.
The estimated frequency of MECP2 mutations in boys with mental retardation is 1.3-1.7% [54].
Typical Rett syndrome features have been observed almost exclusively in boys with Klinefelter
syndrome (47,XXY) [55] or somatic mosaicism for a MECP2 mutation [56, 57]. Other pheno‐
types include severe congenital encephalopathy with death in the first years of life [58-60] and
mild to severe intellectual disability with or without various neurological and psychiatric
symptoms [54, 61]. The most common MECP2 mutations detected in males are duplications
of the whole MECP2 gene (and usually genes in its vicinity). This finding indicates that, besides
the lack, an overabundance of fully functional MeCP2 protein is also harmful to the CNS.
MECP2 duplication syndrome is usually very mild or does not manifest in females. In boys,
this syndrome is characterized by infantile hypotonia, severe mental retardation, loss of
speech, recurrent respiratory infections, seizures, and spasticity [62-64].
In females, MECP2 mutations have been detected in patients with mild mental retardation,
learning disabilities or autism [65, 66]. More severe cases include severe mental retardation
with seizures and Angelman-like syndrome [67, 68].
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3.5. MeCP2 protein
The MeCP2 protein is ubiquitously expressed, but it is particularly abundant in the brain [41,
69]. The protein levels are low during embryogenesis, but they progressively increase during
postnatal neuronal maturation and synaptogenesis [70-75]. High expression of MeCP2 in
mature neurons implies its involvement in postmitotic neuronal functions, such as the
modulation of neuronal activity and plasticity [12].
MeCP2 occurs in two isoforms that arise from alternative splicing of exon 2, and they differ
only by their N-termini (Figure 2). MeCP2 e1 (498 amino acids), generated by exons 1, 3, and
4, is the dominant MeCP2 isoform in the brain [76-78]. The MeCP2 e2 isoform (486 amino acids)
is encoded by exons 2, 3, and 4. Both isoforms were initially assumed to be functionally
equivalent, but recent observations imply that additional isoform-specific functions may exist.
This idea is strongly supported by the fact that no mutations in exon 2 have been found in Rett
syndrome patients, which contrasts with the finding of identified mutations in exon 1. Thus,
defects in MeCP2 e2 may lead to non-Rett phenotypes or fatally affect embryo viability [79, 80].
MeCP2 e1
ATG
MECP2
1 2 3 4
polyA
(1.8 kB)
polyA
(5.4 kB)
polyA
(7.5 kB)
polyA
(10.2 kB)
MeCP2 e1
MeCP2 e2
ATG
MeCP2 e2
          MAAAAAAAPSGGGGGGEEERL
   MVAGMLGLR
MBD: methyl-CpG-binding domain, TRD: transcriptional repression domain, C-ter: C-terminal domain, yellow boxes:
nuclear localization signals.
Figure 2. MECP2 gene structure and the isoforms MeCP2 e1 and MeCP2 e2 with different N-termini due to alternative
splicing of exon 2 and different translation start sites.
Apart from different N-terminal regions, both isoforms share the same amino acid sequence,
including at least three functional domains and two nuclear localization signals (Figure 2). The
methyl-CpG-binding domain (MBD) (amino acids 78-162) mediates binding to symmetrically
methylated CpG dinucleotides [81, 82], with a preference for CpGs with adjacent A/T-rich
motifs [83]. The MBD also binds to unmethylated four-way DNA junctions, which suggests
the role of MeCP2 in higher-order chromatin interactions [84]. The transcriptional repression
domain (TRD) (amino acids 207-310) interacts with numerous proteins, such as co-repressor
factors and histone deacetylases, HDAC1 and HDAC2. The nuclear localization signals (NLS)
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(amino acids 173-193 and 255-271) mediate transportation of the protein into the nucleus [85].
The C-terminal domain (amino acids 325-486) facilitates binding to DNA [86] and it most likely
increases protein stability [87]. This domain also contains conserved poly-proline motifs that
can bind to group II WW domain splicing factors [88].
3.6. MeCP2 function
The original model suggested that MeCP2 is a global transcriptional repressor [89], and it was
based on in vitro experiments in which MeCP2 inhibited transcription from methylated
promoters. Briefly, the protein binds to the promoters of target genes via its MBD, and the TRD
then recruits the co-repressor Sin3A and HDACs [90, 91]. These interactions lead to the
deacetylation of histones, resulting in chromatin condensation and the repression of down‐
stream genes. In addition to Sin3A, other co-repressors, such as c-Ski and N-CoR, may interact
with MeCP2 [92]. The compaction of chromatin can also be promoted through direct interac‐
tion with the C-terminal domain [93], which is an example of HDAC-independent MeCP2-
mediated transcriptional repression. The TRD may also directly interact with transcription
factor IIB; therefore, MeCP2 may silence transcription by interfering with the assembly of the
transcriptional preinitiation complex [94]. Additional factors interacting with the TRD include
Brahma, which is a catalytic component of the SWI/SNF-related chromatin-remodeling
complex (at least in NIH 3T3 cells) [95], DNA methyltransferase 1 [96], and ATRX, a SWI2/
SNF2 DNA helicase/ATPase [97].
Surprisingly, transcriptional profiling studies did not reveal major gene expression changes
caused by the lack of functional MeCP2 protein [98, 99]. These observations, together with
additional evidence, implied that MeCP2 regulates the transcription of tissue-specific genes in
specific brain regions during certain developmental stages instead of acting as a global
repressor [98, 100-102]. However, recent studies suggest that MeCP2 reduces genome-wide
transcriptional noise, potentially by repressing spurious transcription of repetitive elements
[103, 104]. Surprisingly, MeCP2 also interacts with the transcriptional activator CREB, and its
genomic distribution is often associated with actively transcribed genes [105, 106]. MeCP2
apparently has dual roles in transcriptional regulation as a repressor and as an activator, and
it performs different downstream responses depending on the context.
MeCP2 additionally acts as an architectural chromatin protein that is involved in chromatin
remodeling and nucleosome clustering, which is consistent with the fact that the majority of
MeCP2-binding sites are located outside of genes [105, 107]. MeCP2 can bind in vitro to
chromatin fibers and compact them into higher order structures [93, 108, 109].
For further complexity, MeCP2 may also be involved in RNA splicing. Its interaction with the
RNA-binding protein Y box-binding protein 1 (YB-1) has been observed, and MeCP2-deficient
mice showed aberrant alternative splicing patterns [110].
MeCP2 functions are undeniably much more complex than initially anticipated (Figure 3),
although the precise mechanisms of their regulation remain unknown.
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Figure 3. Representation of multiple MeCP2 roles [111].
3.7. MeCP2 target genes
A comprehensive knowledge of the target genes that are controlled by MeCP2 is essential for
understanding the pathomechanisms of Rett syndrome and subsequently developing effective
therapeutic strategies. Multiple studies have attempted to identify genes with altered expres‐
sion in neuronal and nonneuronal tissues from Rett syndrome patients and mouse models,
but these studies have often yielded conflicting results [102, 106, 112, 113]. Nevertheless,
several candidate target genes have been proposed (Table 2). One of the most extensively
studied target genes is the brain-derived neurotrophic factor gene (Bdnf), which has been
shown to be up and down regulated in an activity-dependent manner through MeCP2
phosphorylation in mice [113-115]. Other targets, such as the imprinted genes Dlx5 and Dlx6,
also revealed a novel mode of gene repression mediated by MeCP2 through the formation of
a silent chromatin loop (Figure 3) [116, 117].
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Gene Function Reference
UBE3A member of ubiquitin proteasome pathway, transcriptional co-activator [118]
GABRB3 neurotransmission (GABA-A receptor) [118]
PCDHB1 cell adhesion [119]
PCDH7 cell adhesion [119]
Bdnf neuronal development and survival, neuronal plasticity, learning and memory
(brain derived neurotropic factor)
[113, 114]
Dlx5 neuronal transcription factor (probably involved in control of GABAergic
differentiation)
[116]
Sgk1 hormone signaling (regulation of renal functions and blood pressure) [120]
Fkbp5 hormone signaling (regulation of glucocorticoid receptor sensitivity) [120]
Uqcrc1 member of mitochondrial respiratory chain [121]
ID1, ID2, ID3, ID4transcription factors (involved in cell differentiation and neural development) [122]
FXYD1 ion channel regulator [123]
IGFBP3 hormone signaling (regulation of cell proliferation and apoptosis) [124]
GDI1 regulation of GDP/GTP exchange [112]
APLP1 enhancer of neuronal apoptosis [112]
CLU Extracellular molecular chaperone [112]
Crh neuropeptide (regulation of neuroendocrine stress response) [125]
Table 2. Some of MeCP2 target genes.
3.8. The effect of MECP2 mutations on MeCP2 function
Mutations in the MECP2 gene are not likely to act in a dominant-negative mechanism because
only one allele is active in each female cell due to XCI. The functional consequences of missense
mutations on the function of the MeCP2 protein are sometimes especially difficult to predict.
This difficulty is because testing the protein’s various functions can be problematic because
there are still many MeCP2 roles that are as yet unknown or not fully understood. Generally,
mutations in the NLS prevent the transportation of the protein to the nucleus. Mutations
located within the MBD reduce the affinity of the protein for methylated DNA [87, 126].
However, several mutant proteins with mutations in the MBD have been shown to bind to
heterochromatin [127]. Proteins with an intact MBD but with a mutated TRD retain their ability
to bind to methylated DNA, but they have impaired repressing activity [87]. Other mutations
may affect the stability or the structure (secondary or tertiary) of the protein, and they may
interfere with other functions of the protein.
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3.9. Genotype-phenotype correlation
The severity of the clinical manifestations in Rett syndrome patients is widely variable and is
relevant beyond the context of classic vs. atypical variants. Therefore, much effort has been
devoted to uncovering the relationships between various MECP2 mutations and the variability
of clinical features. Such knowledge may provide information on the likely clinical profile of
new cases with specific MECP2 mutations and may be useful in designing specific preventive
therapeutic interventions.
The general genotype-phenotype correlations were confirmed by numerous studies. As
expected, patients with early truncating mutations (specifically p.R168X, p.R270X, p.R255X),
large deletions of several exons, or the entire MECP2 gene usually have the most severe clinical
presentations. A milder phenotype is often associated with late truncating mutations that do
not affect the MBD or the TRD, such as p.R294X. Interestingly, late truncating mutations
together with the missense mutation p.R133C, which is located in the MBD, are frequently
detected in patients with a preserved speech variant of Rett syndrome [128-133].
Despite some overall trends, considerable variability in clinical severity is often observed
among patients with the same MECP2 mutation [128, 130, 134]. Such variations may be caused
by a different XCI pattern. Favorable skewing of XCI has been observed in some patients with
milder phenotypes [135-137] and in asymptomatic carrier mothers [58, 135, 138]. However,
XCI cannot be used as the single predictor because, according to several studies, it has
limitations in explaining all of the differences of Rett syndrome severity [139-141]. Other
modulation factors have been considered, such as BDNF [142, 143] and APOE [144].
3.10. Genetic counseling
A negative result from the MECP2 analysis (usually including analysis of the entire coding
region and copy number analysis of large deletions/duplications) does not rule out the
diagnosis of Rett syndrome because regulatory and non-coding regions are not routinely
analyzed. The recurrence risk in a family with a single Rett syndrome case and an otherwise
negative family history is very low (less than 0.5%) because the majority of MECP2 mutations
arise de novo. Mothers of the patients, however, should be tested for MECP2 mutations found
in their daughters to rule out the possibility of being asymptomatic carriers. In such case, the
recurrence risk is 50%. Prenatal diagnosis may be performed even in pregnancies of non-carrier
mothers due to the likelihood of germline mosaicism.
4. Management of Rett syndrome
Currently, there is no effective cure for Rett syndrome. However, hopes for developing a
targeted therapy have risen following the announcement of a study that rescued the patho‐
logical phenotype in a mouse model after postnatal reactivation of Mecp2 [145, 146]. Treatment
strategies are currently symptomatic and preventive. These strategies are aimed at ameliorat‐
ing specific symptoms, such as seizures, mood disturbances, sleeping and feeding problems,
as well as maintaining and improving motor and communication functions.
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Rehabilitation programs and physical  therapy help to  control  and improve balance and
movement, maintain flexibility and strengthen muscles. These programs should be adapted
to the patient’s individual state and needs. Proper physical therapy is also important for
preventing joint contractures and other deformities, such as scoliosis. Occupational therapy
is  recommended for  improving  purposeful  hand use  and to  attenuate  stereotypic  hand
movements. Particular care should be taken to preserve and maintain alternative commu‐
nication (eye contact,  eye pointing, facial expressions, signs, etc.)  and thereby improving
social interactions. Receiving necessary nutrients and maintaining an adequate weight may
result in improved growth. To ensure appropriate caloric and nutritional intake, a high-
fat, high-calorie diet or gastrostomy feeding may be required. Sufficient intake of fluid and
high-fiber food is necessary to prevent constipation. The patients with cardiac conduction
defects  (such as  prolonged QTc  intervals)  should avoid certain  medications,  which may
worsen  the  condition.  These  medications  include  several  antipsychotics  (thioridazine,
tricyclic  antidepressants),  certain  antiarrhythmics  (quinidine,  sotalol,  amiodarone),  and
antibiotics (erythromycin) [147].
Early diagnosis and intervention, together with life-long management focused on each
patient’s specific needs, can significantly improve the health, quality of life, and longevity of
patients with Rett syndrome.
5. Conclusion
Much progress has been made in the identification of the multiple roles of the MeCP2 protein
in the brain since its discovery. Nevertheless, many mysteries still remain in understanding
the precise mechanisms of how MECP2 mutations affect protein function and subsequently
contribute to the pathogenesis of Rett syndrome. A significant phenotypic overlap between
Rett syndrome and several neurodevelopmental disorders implies that a common pathogenic
process may induce or at least contribute to these conditions. The identification of pathogenic
MECP2 mutations in a portion of patients without the classic Rett syndrome phenotype
strengthens this theory. Understanding the molecular pathology underlying Rett syndrome
will therefore shed more light on the role of epigenetic modifications in neuronal development
and function, and it may provide insight into the pathogenesis of other neurodevelopmental
disorders.
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